Sandoz reiterates FY 2026 constant-currency sales growth outlook of mid-to-high single digits in pre-close brief

(AWP Alliance News) - Sandoz published a pre-close brief ahead of its H1 2026 results, due on Aug. 5, 2026. The company kept its full-year outlook for mid-to-high single-digit net sales growth at constant currencies. It continued to target about 100 basis points of core EBITDA margin expansion, weighted to the second half.

It flagged no material contribution from any potential generic semaglutide launch in 2026, with overall pricing expected to fall by a low-to-mid single-digit percentage. It also pointed to a company-collected May consensus for net sales growth of 6% in Q2, 6.7% for the full year.

https://docs.publicnow.com/E544AF60CE382C9F90746F90540E17B7FD905AA9

Disclaimer: This news brief was created using generative artificial intelligence. Sandoz Group AG published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.